Risk Stratification and MRD-driven Maintenance for MM After ASCT

NCT06697483 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: Lenalidomide

Sponsor

Peking University People's Hospital